A review of the use of cefotaxime in the treatment of skin and skin structure infections, with special reference to gram-positive pathogens

Infection

Volumn 13, Issue 1 Supplement, 1985, Pages

  Karakusis, P H ^a   Trenholme, G M ^a   Levin, S ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; PENICILLIN G;

ADVERSE DRUG REACTION; ANEMIA; BLOOD AND HEMOPOIETIC SYSTEM; CELLULITIS; DIGESTIVE SYSTEM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG THERAPY; DRUG TOXICITY; EOSINOPHILIA; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INJECTION PAIN; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PERIPHERAL VASCULAR SYSTEM; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RASH; SKIN ABSCESS; SKIN INFECTION; SKIN TOXICITY; SOFT TISSUE; STAPHYLOCOCCUS AUREUS; SURVEY; THERAPY; THROMBOPHLEBITIS; URTICARIA; VERTIGO;

BACTERIAL INFECTIONS; CEFOTAXIME; GRAM-POSITIVE BACTERIA; HUMAN; SKIN DISEASES, INFECTIOUS;

EID: 0022388791     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/BF01644218     Document Type: Review

References (20)

1. Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli
2. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli
3. The new beta-lactamase-stable cephalosporins
4. Clinical evaluation of moxalactam
5. Treatment of serious infections with moxalactam
6. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use
7. Clinical efficacy of cefotaxime in serious infections
8. Clinical evaluation in a community hospital
9. Cefotaxime in serious infections — a clinical and pharmacokinetic study
10. Cefotaxime therapy in children with serious infections associated with reduced host defense mechanisms
11. Use of cefotaxime, a β-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms
12. Clinical evaluation of moxalactam: Evidence of decreased efficacy in gram-positive aerobic infections
13. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic
14. Cefotaxime in the treatment of infections of the skin and skin structure
15. Cefotaxime therapy of serious infections with multiresistant gram-negative bacilli
16. Clinical comparison of cefotaxime with gentamicin plus clindamycin in the treatment of peritonitis and other soft-tissue infections
17. Clinical experience with cefotaxime in obstetric and gynecologic infections
18. Medium-dependent zone size discrepancies associated with susceptibility testing of group D streptococci against various cephalosporins